Core Viewpoint - Jingtai Holdings (02228) has seen a significant stock increase of nearly 7%, currently trading at 7.58 HKD with a transaction volume of 669 million HKD, following a major partnership announcement with DoveTree [1] Company Summary - On August 5, Jingtai Technology announced a pipeline collaboration with DoveTree, with a total order value of approximately 47 billion HKD, and has received an initial payment of 400 million HKD [1] - The collaboration involves the development of multiple innovative drug assets, granting DoveTree exclusive global development and commercialization rights [1] - Jingtai Technology is expected to receive further payments and potential milestone payments totaling around 46.6 billion HKD from this partnership [1] Industry Summary - This collaboration sets a new record in the AI and robotics drug development sector [1] - Dongwu Securities highlighted that DoveTree LLC was founded by Professor Gregory Verdine, a prominent figure in chemical biology and a Harvard University professor, who has established or co-founded over ten biotech companies, including five publicly listed ones [1] - The total package amount for this commercial collaboration is valued at 5.89 billion USD, exceeding market expectations, and the backing from a Harvard professor suggests that the pipeline may achieve its commercial milestones, indicating significant future growth potential for the company [1]
港股异动 | 晶泰控股(02228)再涨近7% 公司与DoveTree达成AI新药合作 商业合作金额超出市场预期